知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.042 秒)

    DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
    41.
    发明申请
    DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS 审中-公开

    公开(公告)号：US20190336536A1

    公开(公告)日：2019-11-07

    申请号：US16212497

    申请日：2018-12-06

    申请人： Magenta Therapeutics, Inc.

    发明人： Dwight Morrow ,  Patrick C. Falahee ,  Anthony Boitano ,  Michael P. Cooke ,  Kevin A. Goncalves

    IPC分类号： A61K35/28 ,  A61P37/00 ,  A61K31/4427 ,  A61K45/06 ,  C12N5/0789

    摘要： The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.

    COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS
    42.
    发明申请
    COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS 审中-公开

    公开(公告)号：US20190328901A1

    公开(公告)日：2019-10-31

    申请号：US16310738

    申请日：2017-06-19

    申请人： MAGENTA THERAPEUTICS, INC.

    发明人： Andrew NIXON ,  Dwight MORROW ,  Adam HARTIGAN

    IPC分类号： A61K47/68 ,  C07K16/28 ,  A61K35/28 ,  A61K39/395 ,  A61K38/12 ,  A61K31/704 ,  A61K38/07 ,  A61K31/4745 ,  A61K31/5517

    摘要： The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

    COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
    43.
    发明申请
    COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS 审中-公开

    公开(公告)号：US20190314407A1

    公开(公告)日：2019-10-17

    申请号：US16177252

    申请日：2018-10-31

    申请人： Magenta Therapeutics Inc.

    发明人： Anthony BOITANO ,  Michael COOKE ,  Kevin A. GONCALVES

    IPC分类号： A61K35/12 ,  C12P21/00 ,  C12N5/0789

    摘要： Provided herein are compositions and methods useful for the expansion of hematopoietic stem and progenitor cells, such as those that have been genetically modified, for instance, to express a heterologous transgene. In accordance with the composition and methods described herein, hematopoietic stem and progenitor cells may be genetically modified, for example, to express transgenes encoding therapeutic proteins. Genetically modified hematopoietic stem and progenitor cells may be expanded, for instance, by treatment ex vivo with an aryl hydrocarbon receptor antagonist, and may be infused into a patient, such as a patient in need of hematopoietic stem cell transplant therapy. Thus, provided herein are methods for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.

    COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS
    46.
    发明申请
    COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS 审中-公开

    公开(公告)号：US20190153114A1

    公开(公告)日：2019-05-23

    申请号：US16168823

    申请日：2018-10-23

    申请人： Magenta Therapeutics, Inc.

    发明人： Bradley R. Pearse ,  Michael Cooke ,  Anthony Boitano ,  Rahul Palchaudhuri ,  Sean McDonough ,  Rajiv Panwar ,  Jacob Glanville

    IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K35/545 ,  A61K47/68 ,  C07K7/64 ,  A61P37/06

    摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

    ANTI-CD117 ANTIBODIES AND USES THEREOF
    49.
    发明申请
    ANTI-CD117 ANTIBODIES AND USES THEREOF 有权

    公开(公告)号：US20220177578A1

    公开(公告)日：2022-06-09

    申请号：US17508766

    申请日：2021-10-22

    申请人： Magenta Therapeutics, Inc.

    发明人： Rahul Palchaudhuri ,  Anthony Boitano ,  Michael Cooke ,  Bradley R. Pearse

    IPC分类号： C07K16/28

    摘要： The present disclosure provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.